Rooks, Daniel
Article History
First Online: 25 July 2019
Compliance with Ethical Standards
:
: Daniel Rooks has a patent for the use of bimagrumab in sarcopenia pending. In addition, he is a full time employee of the Novartis Institutes of BioMedical Research. However, Dr. Rooks reports that no recommendation or data regarding any drug developed by or marketed by Novartis is included in the manuscript, and that the focus of the paper is non-drug approaches to care for sarcopenia.
: This article does not contain any studies with animal subjects performed by any of the authors.